title: Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
authors.forename: Wing-Yan
authors.initials: WY
authors.lastname: Au
authors.forename: Sidney
authors.initials: S
authors.lastname: Tam
authors.forename: Bonnie M
authors.initials: BM
authors.lastname: Fong
authors.forename: Kwan-Lun
authors.initials: KL
authors.lastname: Ho
authors.forename: Po-Chor
authors.initials: PC
authors.lastname: Tam
authors.forename: Yok-Lam
authors.initials: YL
authors.lastname: Kwong
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001151:Arsenic / Q000652:urine; D020261:Arsenic Poisoning / Q000150:complications / Q000652:urine; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage* / Q000009:adverse effects*; D016022:Case-Control Studies; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D053040:Nephrolithiasis / Q000139:chemically induced*; D010087:Oxides / Q000008:administration & dosage* / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D001151:Arsenic; D000077237:Arsenic Trioxide